We have collected information about Drug Delivery Of Sirna Therapeutics for you. Follow the links to find out details on Drug Delivery Of Sirna Therapeutics.
https://www.mdpi.com/1999-4923/12/2/178/pdf
This Special Issue of Pharmaceutics titled “Drug Delivery of siRNA Therapeutics” aims to present the state of the art of siRNA delivery, embracing investigation strategies of international research groups with di erent experiences and skills. The Special Issue will thus be devoted to presentingAuthor: Gaetano Lamberti, Anna Angela Barba
https://www.sciencedirect.com/science/article/pii/S1549963408000828
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. ... the delivery of RNAi therapeutics must use a targeting technology that permits the RNAi therapeutic to cross biological membrane barriers. For the above-mentioned reasons, there is a need for suitable carriers that will provide a stable complex and protection to ...Author: Daniela Reischl, Andreas Zimmer
https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_delivery_of_siRNA_therapeutics
After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. Full article
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.ddw-online.com/therapeutics/p322575-current-trends-in-rna-therapeutics-development.html
Furthermore, the new chemistries confer drug-like properties to RNA, reduce immune stimulation, maximise on-target potency and prolong the duration of the drug. Delivery of RNA therapeutics. RNA-based therapeutics must be delivered to the target cell and enter the cell to be active (8) (Figure 1).
https://www.ncbi.nlm.nih.gov/pubmed/32093141
Feb 20, 2020 · Drug Delivery of siRNA Therapeutics. Lamberti G(1)(2), Barba AA(1)(3). Author information: (1)Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy. (2)Dipartimento di Ingegneria Industriale; Università degli Studi di Salerno, via Giovanni Paolo II, 132 84084 Fisciano (SA), Italy.Author: Gaetano Lamberti, Anna Angela Barba
https://www.nature.com/articles/s41573-019-0017-4
Mar 07, 2019 · The recent approval of the first RNA interference (RNAi)-based therapy has generated considerable excitement in the field. Here, Rossi and colleagues discuss key advances in the design and ...Author: Ryan L. Setten, Ryan L. Setten, John J. Rossi, John J. Rossi, Si-ping Han, Si-ping Han
https://www.hindawi.com/journals/jdd/2017/6971297/
Over the past 20 years, a diverse group of ligands targeting surface biomarkers or receptors has been identified with several investigated to target siRNA to tumors. Many approaches to developing tumor-homing peptides, RNA and DNA aptamers, and single-chain variable fragment antibodies by using phage display, in vitro evolution, and recombinant antibody methods could not have been imagined by ...Author: Qixin Leng, Martin C. Woodle, A. James Mixson
https://www.sciencedirect.com/science/article/pii/S1818087614000646
The attitude of big pharmaceutical companies to RNAi drugs has also become over-optimistic. In summary, a good delivery system is the key to siRNA drug development. Once research into siRNA drug delivery systems makes a significant breakthrough, siRNA will occupy a strong position in the drug market, especially the anti-cancer drug market.Author: Cong-fei Xu, Jun Wang
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0450-0
Jun 27, 2017 · Alnylam Pharmaceuticals, in particular, has several siRNA drugs in clinical trials. Their most advanced drug, also one of the most advanced siRNA therapeutics, patisiran, is a LNP containing siRNA against mutant transthyretin for the treatment of transthyretin amyloidosis .Author: James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson
Searching for Drug Delivery Of Sirna Therapeutics?
You can just click the links above. The data is collected for you.
